Is Titan Biotech overvalued or undervalued?

As of 12 June 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 16.50, an EV to EBITDA of 13.86, and a Price to Book Value of 2.32. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Titan Biotech's PE ratio is notably lower than that of Solar Industries, which stands at 124.55, and Godrej Industries, which has a PE of 44.06, both of which are also categorized as very expensive. This highlights that while Titan Biotech is overvalued, it is not as extreme as some of its competitors. Additionally, the company's recent stock performance shows a 1-week return of 3.43%, outperforming the Sensex's 0.31%, but it has underperformed over longer periods, with a year-to-date decline of 41.32% compared to the Sensex's gain of 4.55%.